Apixaban for Cerebral Hemorrhage

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Cerebral Hemorrhage+2 More
Apixaban - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.

Eligible Conditions
  • Cerebral Hemorrhage
  • Atrial Fibrillation

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Cerebral Hemorrhage

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 3 years

Month 12
Modified Rankin Scale (mRS) score
Up to 3 years
Stroke or death

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Cerebral Hemorrhage

Trial Design

2 Treatment Groups

Apixaban
1 of 2
Aspirin
1 of 2
Active Control
Non-Treatment Group

700 Total Participants · 2 Treatment Groups

Primary Treatment: Apixaban · Has Placebo Group · Phase 3

Aspirin
Drug
PlaceboComparator Group · 1 Intervention: Aspirin · Intervention Types: Drug
Apixaban
Drug
ActiveComparator Group · 1 Intervention: Apixaban · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,666 Previous Clinical Trials
21,074,090 Total Patients Enrolled
6 Trials studying Cerebral Hemorrhage
3,013 Patients Enrolled for Cerebral Hemorrhage
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,250 Previous Clinical Trials
451,653 Total Patients Enrolled
20 Trials studying Cerebral Hemorrhage
21,293 Patients Enrolled for Cerebral Hemorrhage
Kevin N Sheth, MDPrincipal InvestigatorYale School of Medicine
1 Previous Clinical Trials
88 Total Patients Enrolled
Hooman Kamel, MDPrincipal InvestigatorWeill Medical College of Cornell University

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
You have atrial fibrillation or atrial flutter.
You have a CHA2DS2-VASc score ≥ 2.
You have signed and dated an informed consent form.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.